A retrospective clinical series from Peking University reports early experience using the Jingfeng MP1000 multi-port robotic surgical system for robotic laparoscopic radical nephrectomy combined with venous tumor thrombectomy in patients with renal cell carcinoma (RCC). The series included 15 patients treated between June 2024 and January 2026, encompassing renal venous tumor thrombi ranging from Mayo grade 0 to grade III.
All procedures were successfully completed robotically without conversion to open surgery. The median operative time was 233 minutes, median estimated blood loss was 250 mL, and approximately one-third of patients required perioperative blood transfusion. Median postoperative hospitalization was six days.
Early morbidity was relatively limited for such technically demanding surgery. One patient developed a Clavien-Dindo grade II lymphatic leak, while no grade III or higher complications and no perioperative deaths were reported. Histopathology demonstrated predominantly clear-cell RCC, and venous wall invasion was identified in more than half of the patients.
These findings are encouraging, but the small cohort and short follow-up mean the study should primarily be interpreted as evidence of technical feasibility and perioperative safety, rather than proof of long-term oncological equivalence.
Surgical Relevance
Radical nephrectomy with venous tumor thrombectomy represents one of the most technically challenging applications of minimally invasive urological surgery. Successful robotic management requires meticulous renal hilar dissection, vascular control, thrombus localization, prevention of embolization, venotomy and vascular reconstruction, together with continuous readiness for major hemorrhage or open conversion.
The report is also relevant to the wider robotic surgical community because it demonstrates the expanding use of alternative robotic platforms for highly complex procedures traditionally associated with established robotic systems.
For advanced laparoscopic and robotic surgeons, the fundamental message remains that technological capability must be supported by vascular surgical expertise, appropriate patient selection, multidisciplinary preparation, blood-product availability, and a clearly defined conversion strategy.
Clinical Takeaway: Robotic radical nephrectomy with venous tumor thrombectomy appears technically feasible in carefully selected patients and experienced centers, but larger studies with longer oncological follow-up are required before broader conclusions can be drawn.
Source: PubMed – Robotic Radical Nephrectomy With Venous Tumor Thrombectomy
Laparoscopic Nephron-Sparing Surgery Can Preserve Renal Units in Selected Giant Angiomyolipoma
A second retrospective study from Peking University evaluated minimally invasive nephron-sparing surgery for giant renal angiomyolipoma (AML), defined as tumors measuring at least 8 cm. The study included 45 patients treated between 2012 and 2025, with a mean tumor diameter of approximately 10.3 cm.
Standard laparoscopy was used in 39 patients, while six underwent robotic-assisted laparoscopic surgery. A retroperitoneal approach was preferred in most cases, providing direct access to the kidney and renal hilum while avoiding unnecessary intraperitoneal dissection.
Complete tumor removal with preservation of the affected kidney was achieved in all patients. However, five procedures required conversion to open surgery, primarily because of difficult adhesions or intraoperative bleeding. Mean operative time was approximately 181 minutes, while mean warm ischemia time was 22 minutes, with most procedures maintaining warm ischemia below 30 minutes.
Postoperative morbidity was limited, with one pulmonary infection and one episode of renal insufficiency reported. During follow-up ranging from approximately three to 43 months, the investigators reported no tumor recurrence or major deterioration in renal function.
Surgical Relevance
Giant renal angiomyolipomas present a difficult balance between hemorrhage control and preservation of functioning renal parenchyma. Their large size and vascularity can make minimally invasive resection technically demanding, particularly when tumors distort the renal hilum or are associated with extensive adhesions.
The study reinforces several principles applicable beyond renal surgery: careful preoperative imaging, appropriate choice of surgical approach, early vascular control, disciplined warm-ischemia management, meticulous reconstruction, anticipation of major bleeding, and timely conversion when minimally invasive safety is compromised.
Conversion should not be regarded as technical failure. In highly vascular solid-organ surgery, early conversion may represent the safest operative decision when bleeding, adhesions, or anatomical uncertainty prevent controlled laparoscopic progression.
Clinical Takeaway: Laparoscopic or robotic nephron-sparing surgery can preserve renal function even in selected giant angiomyolipomas, but successful minimally invasive management depends on careful selection, vascular control, ischemia discipline, reconstructive expertise, and a low threshold for conversion when necessary.
Source: PubMed – Laparoscopic Nephron-Sparing Surgery for Giant Renal Angiomyolipoma
Key Message
The 18 August 2026 evidence update demonstrates how advanced minimally invasive and robotic surgery is progressively extending into complex vascular and organ-preserving procedures. Robotic nephrectomy with venous tumor thrombectomy illustrates the potential of modern robotic platforms in high-risk vascular surgery, while laparoscopic nephron-sparing surgery for giant angiomyolipoma demonstrates that even large vascular renal tumors may sometimes be treated while preserving functioning renal tissue.
Across both studies, the decisive factors remain careful patient selection, detailed preoperative imaging, secure vascular control, meticulous surgical technique, hemorrhage preparedness, disciplined reconstruction, and timely conversion when patient safety requires it.
Technology expands what is technically possible; surgical judgment determines what is safely appropriate.
